Investors sentiment decreased to 0.98 in 2017 Q2. Its down 0.13, from 1.11 in 2017Q1.
Hedge funds have recently added to or reduced their stakes in the company. (NASDAQ:SAGE). State Board Of Administration Of Florida Retirement System owns 12,742 shares for 0% of their portfolio. (NASDAQ:SAGE). Ameritas Investment Prns Inc has invested 0.01% in Sage Therapeutics, Inc.
Nuveen Asset Ltd Liability holds 0% or 3,437 shares in its portfolio. (NASDAQ:SAGE). Susquehanna Limited Liability Partnership holds 45,032 shares or 0% of its portfolio.
Ratan Mgmt L P accumulated 1.64% or 50,000 shares. Cwm Llc owns 6 shares. (NASDAQ:SAGE) for 5,296 shares. (NASDAQ:SAGE). Parametric Portfolio Assoc Ltd Limited Liability Company holds 0% or 22,535 shares in its portfolio. Voloridge Inv Mngmt Lc stated it has 0.15% in Sage Therapeutics, Inc. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company's stock valued at $3,276,000 after purchasing an additional 3,551 shares during the period. Palo Alto Investors Ltd reported 3.84% in Sage Therapeutics, Inc. Jpmorgan Chase & Com holds 0.01% or 818,671 shares in its portfolio.
SAGE-217 was found to be safe, with no serious adverse events reported. (NASDAQ:SAGE) for 12,199 shares. The 1-year high was reported on Dec, 7 by Barchart.com. We have $169.11 PT which if reached, will make NASDAQ:SAGE worth $393.00 million more.
The stock increased 74.90% or $68.83 during the last trading session, reaching $160.73. About 6.95M shares traded or 716.67% up from the average. (NASDAQ:SAGE) for 54,625 shares. It has outperformed by 99.75% the S&P500.
The data, according to a note from Leerink Partners analyst Paul Matteis, are a "best-case scenario" for Sage.
SAGE has been the topic of several other research reports. After $-1.97 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.52 % negative EPS growth. Therefore 88% are positive. Lake Street initiated it with "Buy" rating and $90 target in Friday, March 11 report. The company was maintained on Thursday, November 2 by RBC Capital Markets. The firm has "Buy" rating by Cowen & Co given on Thursday, August 3. SAGE Therapeutics has a 1-year low of $26.55 and a 1-year high of $75.49.
Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. The firm presently has a "sell" rating on the biopharmaceutical company's stock. (NASDAQ:SAGE) on Wednesday, February 22 to "Neutral" rating. Finally, BlackRock Fund Advisors boosted its position in shares of SAGE Therapeutics by 14.6% in the third quarter. Canaccord Genuity maintained it with "Buy" rating and $11000 target in Friday, August 4 report. The company was initiated on Tuesday, September 13 by Raymond James.
And for Sage, helping lift depression in patients could generate $1 billion or more in sales. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since December 7, 2016 and is uptrending. Businesswire.com's news article titled: "Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635 (c)(4)" with publication date: December 04, 2017 was also an interesting one. It's hard to understate how meaningful these data are in the backdrop of the very significant unmet medical need in depression: even if the SAGE data on a placebo-adjusted basis weren't differentiated via cross-trial comparisons, we still think '217 would be an important drug as it offers a new mechanism (extra-synaptic GABA-modulation) in an area where the vast majority of options generally modulate the same pathways (serotonin, dopamine, norepinephrine). Royal Bank Of Canada's price target would indicate a potential upside of 79.18% from the company's current price. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. It now has negative earnings.
Sage Therapeutics (NASDAQ:SAGE) is up 52% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.
- Senior Palestinian Official: Vice President Pence Not Welcome In Palestine
- Morocco: Dubai International Film Festival Opens With Morocco's Participation
- Angry Birds, Sonic coming to Facebook Messenger games
- King Salman warns against embassy move to Jerusalem
- Holiday decorating safety tips that save lives
- Cabot Oil & Gas (COG) Price Target Raised to $32.00 at Barclays
- What the Insider Data Suggests About Rite Aid Corporation (RAD)
- Most Active Stock: Bank of America Corporation (BAC)
- Manchester United best and worst case scenario for Champions League knockout stage
- Bryan Singer reportedly sued for allegedly raping 17-year-old